3560 related articles for article (PubMed ID: 12748652)
1. Osteoclast differentiation and activation.
Boyle WJ; Simonet WS; Lacey DL
Nature; 2003 May; 423(6937):337-42. PubMed ID: 12748652
[TBL] [Abstract][Full Text] [Related]
2. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
[TBL] [Abstract][Full Text] [Related]
5. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
6. Genetic regulation of osteoclast development and function.
Teitelbaum SL; Ross FP
Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways regulating osteoclast differentiation and function.
Tanaka S; Nakamura I; Inoue J; Oda H; Nakamura K
J Bone Miner Metab; 2003; 21(3):123-33. PubMed ID: 12720046
[No Abstract] [Full Text] [Related]
8. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
10. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
11. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
12. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
13. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast stimulating and differentiating factors in human cholesteatoma.
Hamzei M; Ventriglia G; Hagnia M; Antonopolous A; Bernal-Sprekelsen M; Dazert S; Hildmann H; Sudhoff H
Laryngoscope; 2003 Mar; 113(3):436-42. PubMed ID: 12616193
[TBL] [Abstract][Full Text] [Related]
15. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
16. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
19. [Osteoporosis induced by immunosuppressant].
Fukunaga J; Sugahara T
Nihon Rinsho; 2004 Feb; 62 Suppl 2():740-3. PubMed ID: 15035219
[No Abstract] [Full Text] [Related]
20. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
